Identification of subgroups of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone plus prednisone at low vs. high risk of radiographic progression: An analysis of COU-AA-302

Citation:

Martin LJ, Alibhai SMH, Komisarenko M, Timilshina N, Finelli A. Can Urol Assoc J. [Epub ahead of print 5 Nov 2018]. doi: 10.5489/cuaj.5586.